Mark Eisner Sells 2,089 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 2,089 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $7.45, for a total transaction of $15,563.05. Following the sale, the executive vice president directly owned 157,529 shares of the company’s stock, valued at $1,173,591.05. This represents a 1.31% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Vir Biotechnology Trading Up 5.4%

Shares of NASDAQ:VIR opened at $10.00 on Thursday. The firm has a 50 day moving average of $6.88 and a 200-day moving average of $6.02. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.94. The stock has a market capitalization of $1.40 billion, a PE ratio of -3.16 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.11. The business had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm’s revenue for the quarter was up 417.8% on a year-over-year basis. During the same quarter last year, the business posted ($0.76) EPS. On average, research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VIR has been the subject of a number of research analyst reports. Barclays boosted their price target on Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a research note on Monday, December 22nd. Evercore reissued an “outperform” rating and issued a $18.00 target price on shares of Vir Biotechnology in a report on Tuesday. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price target on the stock in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Vir Biotechnology in a research note on Tuesday, December 30th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.88.

Institutional Trading of Vir Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vir Biotechnology by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company’s stock valued at $41,000 after buying an additional 1,390 shares during the period. FNY Investment Advisers LLC acquired a new stake in Vir Biotechnology during the 3rd quarter worth approximately $38,000. Raymond James Financial Inc. bought a new stake in Vir Biotechnology during the 2nd quarter worth approximately $35,000. UMB Bank n.a. grew its holdings in Vir Biotechnology by 1,418.7% during the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock worth $43,000 after acquiring an additional 6,597 shares during the last quarter. Finally, Federated Hermes Inc. increased its position in Vir Biotechnology by 153.8% in the 3rd quarter. Federated Hermes Inc. now owns 8,085 shares of the company’s stock valued at $46,000 after acquiring an additional 4,899 shares during the period. 65.32% of the stock is currently owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.